Compare AIOT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIOT | GYRE |
|---|---|---|
| Founded | 1993 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 665.1M | 755.7M |
| IPO Year | N/A | N/A |
| Metric | AIOT | GYRE |
|---|---|---|
| Price | $5.61 | $7.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $10.50 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.1M | 106.1K |
| Earning Date | 02-09-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $425,867,000.00 | $107,265,000.00 |
| Revenue This Year | $23.71 | $11.59 |
| Revenue Next Year | $9.22 | $26.31 |
| P/E Ratio | ★ N/A | $193.40 |
| Revenue Growth | ★ 92.93 | 2.13 |
| 52 Week Low | $3.70 | $6.11 |
| 52 Week High | $8.71 | $13.75 |
| Indicator | AIOT | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 60.78 | 51.18 |
| Support Level | $5.38 | $6.83 |
| Resistance Level | $5.63 | $7.71 |
| Average True Range (ATR) | 0.19 | 0.35 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 87.96 | 57.63 |
PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.